Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAL-MRE1 in ragweed induced allergic rhinitis
NCT03758456Phase 1Completed
- Sponsor
- HAL Allergy Group
- Start
- Nov 2018
- Primary completion
- May 2019
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hal-mre1 in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by HAL Allergy Group. Primary endpoint: Occurence of local and systemic reactions at 10 weeks. Started Nov 2018; status: completed.
02
Drugs
hal-mre1
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT03758456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758456.